The Pharma Letter5 小时
Gilead’s Livdelzi reduced pruritus severity in PBC participants
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...
The Hearty Soul on MSN10 小时
11 Early and Advanced Symptoms of Cirrhosis You Should Be Aware Of
Understanding the symptoms of cirrhosis can facilitate early diagnosis and intervention, improving outcomes for those ...
The Pharma Letter22 小时
Positive new data for Ipsen’s Iqirvo
The late-breaking presentations (Abstract #5041 and Abstract #5042) report on biomarkers of cholestasis, stabilization of ...
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
Research Analysts Offer Predictions for MIRM Q3 Earnings
Equities researchers at HC Wainwright reduced their Q3 2025 earnings per share (EPS) estimates for shares of Mirum ...